The GLP-1 titration schedule is designed to minimize side effects by starting at a low dose and increasing gradually. But the schedule is a guideline, not a contract. In 2026, clinicians who manage GLP-1 therapy adjust the titration timeline based on individual tolerance, not a fixed calendar. This guide covers how to navigate the titration schedule for semaglutide and tirzepatide without side effects derailing your treatment.
- Titration works by increasing the dose in small increments every 4 weeks so your body can adapt.
- Up to 40% of patients experience side effects significant enough to delay a dose increase — and that delay is clinically appropriate.
- Semaglutide titrates from 0.25mg to 2.4mg over 16-20 weeks; tirzepatide titrates from 2.5mg to 15mg over 20-24 weeks.
- Nausea and constipation peak in the first 2 weeks of each dose increase and should resolve by week 3-4.
- Weight loss typically doesn't start until the second dose level, since starting doses are sub-therapeutic.
- The right schedule is the one that gets you to the therapeutic dose without quitting, even if it takes longer than the default timeline.
TL;DR
GLP-1 titration works by increasing the dose in small increments every 4 weeks, giving your body time to adapt to each dose level. The standard semaglutide schedule goes from 0.25mg to 2.4mg over 16-20 weeks; tirzepatide goes from 2.5mg to 15mg over 20-24 weeks. But up to 40% of patients experience side effects significant enough to delay a dose increase, and that delay is clinically appropriate, not a failure. Tirzepatide dosing, results, and side effects covers the dose ladder in detail. GoodLife Health clinicians adjust the schedule based on your response. Verdict: the titration schedule that works is the one you can tolerate, not the one that moves fastest. Patients who titrate slowly reach the same dose with fewer side effects and better long-term adherence.
Why this matters
The most common reason patients quit GLP-1 therapy is not lack of efficacy — it is side effects during titration. Nausea, constipation, fatigue, and delayed gastric emptying are most intense in the first 2-4 weeks of each dose increase and typically resolve as the body adapts. But if the dose increases before adaptation is complete, side effects compound and adherence collapses.
In 2026, the standard titration schedule remains the default, but clinicians increasingly personalize the timeline. A patient who needs 8 weeks at 0.25mg instead of 4 weeks is not behind — they are on a schedule that matches their physiology. The goal is reaching the therapeutic dose, not reaching it by a specific date.
What you'll need
- Your clinician's titration schedule for your specific medication (semaglutide or tirzepatide)
- A symptom log tracking nausea, constipation, fatigue, and appetite suppression on a daily basis during the first 2 weeks of each dose increase
- A plan for managing common side effects: hydration, meal timing, protein intake, and anti-nausea medication if needed
- Access to your clinician for dose adjustment decisions between scheduled visits
- An understanding that the standard schedule is a default, not a mandate
The steps
1. Understand the standard titration schedule for your medication
For semaglutide (Wegovy): 0.25mg weekly for 4 weeks, then 0.5mg for 4 weeks, then 1.0mg for 4 weeks, then 1.7mg for 4 weeks, then 2.4mg maintenance. Total titration: 16-20 weeks.
For tirzepatide (Zepbound): 2.5mg weekly for 4 weeks, then 5mg for 4 weeks, then 7.5mg for 4 weeks, then 10mg for 4 weeks, then 12.5mg for 4 weeks, then 15mg maintenance. Total titration: 20-24 weeks. How to choose between tirzepatide and semaglutide covers the differences. Common mistake: assuming the schedule is fixed. It is a default. Your clinician should adjust based on your tolerance.
Standard Titration Schedule
Each dose level lasts 4 weeks unless extended
| Step | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| First | 0.25mg | 2.5mg |
| Second | 0.5mg | 5mg |
| Third | 1.0mg | 7.5mg |
| Fourth | 1.7mg | 10mg |
| Fifth | 2.4mg (maintenance) | 12.5mg |
| Sixth | — | 15mg (maintenance) |
2. Track symptoms during the first 2 weeks of each dose increase
Side effects are most intense in the first 2 weeks of a new dose and typically resolve by week 3-4. Log nausea (1-10 scale), constipation (days since last bowel movement), fatigue (1-10 scale), and appetite suppression (too much, too little, or appropriate). This log tells your clinician whether you are ready to increase or should hold the dose longer. Common mistake: not tracking symptoms because they seem mild. Mild symptoms that persist into week 3 are a signal to hold the dose, not push through.
3. Hold the dose if side effects have not resolved by week 3
If nausea, constipation, or fatigue are still significant at week 3 of a dose level, your clinician may recommend holding for an additional 2-4 weeks before increasing. This is not falling behind — it is preventing the side-effect cascade that leads to discontinuation. How to manage nausea on semaglutide covers the symptom management protocol. Common mistake: increasing the dose on schedule despite unresolved side effects because the schedule says to. The schedule does not know your body.
If nausea, constipation, or fatigue are still significant at week 3 of a dose level, holding for an additional 2-4 weeks before increasing is not falling behind — it is preventing the side-effect cascade that leads to discontinuation.
4. Manage nausea proactively, not reactively
Nausea on GLP-1 therapy is worst on an empty stomach and after large meals. Eat small, frequent meals (4-5 per day, 200-300 calories each). Prioritize protein and complex carbohydrates. Avoid high-fat and high-sugar meals, which delay gastric emptying further. If nausea is severe, ask your clinician about ondansetron (Zofran) — 4mg as needed can bridge you through the worst of the titration window. Hydration is critical: aim for 80-100 oz of water per day. Common mistake: trying to power through nausea without any management strategy. Unmanaged nausea is the #1 reason patients quit GLP-1 therapy.
5. Address constipation before it becomes severe
GLP-1 medications slow gastric emptying, which slows the entire GI tract. Constipation is common and manageable: increase fiber gradually (25-30g per day from food, not supplements if possible), increase water intake, and add magnesium citrate (200-400mg at bedtime) if constipation persists. How to manage constipation on tirzepatide covers the full protocol. Common mistake: ignoring constipation until it becomes severe. Severe constipation can cause nausea and abdominal pain that mimic medication intolerance.
6. Time your injection for the side effect window you prefer
Most patients inject in the morning, but the side effect window (nausea peak) typically occurs 12-24 hours after injection. If you inject on Monday morning, nausea peaks Monday evening through Tuesday. Some patients prefer to inject on Friday evening so the peak falls on the weekend when they can rest. Discuss injection timing with your clinician — it does not change efficacy but can change the experience. Common mistake: assuming injection timing does not matter. It does not change results, but it changes how you feel during the worst days.
7. Maintain protein intake even when appetite is suppressed
Appetite suppression is the mechanism of GLP-1 therapy, but it suppresses appetite for protein most of all. When you can only eat a small amount of food, prioritize protein. A protein shake (25-30g) is easier to consume than an equivalent amount of chicken or fish. How to reduce muscle loss when dieting on GLP-1 covers the protein protocol. Common mistake: eating whatever you can tolerate during the nausea window, which is often crackers and toast. Protein first, always.
Troubleshooting
Nausea is severe at week 2 of a new dose. This is common but should be improving by week 2, not worsening. If nausea is worsening, contact your clinician. Options include holding the dose longer, adding ondansetron, or in rare cases, stepping back to the previous dose.
You have not had a bowel movement in 4 days. This is constipation, not a medication emergency, but it needs active management. Increase water and fiber, add magnesium citrate, and if it persists beyond 5 days, contact your clinician. Do not take stimulant laxatives without clinician guidance.
You feel exhausted, not just nauseous. Fatigue on GLP-1 therapy often reflects inadequate calorie intake. If appetite suppression is so strong that you are eating fewer than 1,000 calories per day, your body is underfueling. Talk to your clinician about whether the dose is too high or whether you need a structured meal plan to ensure adequate intake.
Fatigue on GLP-1 therapy often reflects inadequate calorie intake. If appetite suppression is so strong that you are eating fewer than 1,000 calories per day, your body is underfueling.
Your weight loss stalled during titration. This is common at the starting dose. Semaglutide at 0.25mg and tirzepatide at 2.5mg are sub-therapeutic — they are meant to get your body adapted, not to produce significant weight loss. Weight loss typically begins at the second dose level (0.5mg semaglutide, 5mg tirzepatide).
Side effects resolved at the previous dose but returned at the new dose. This is the expected pattern. Each dose increase triggers a new adaptation period. The side effects should be milder than the first time because your body has partially adapted. If they are worse, hold the dose.
The schedule that gets you to the therapeutic dose without quitting is the right schedule — even if it takes 24 weeks instead of 16.
Tools and resources
- A symptom log for nausea, constipation, fatigue, and appetite
- A protein tracking app to ensure adequate intake during appetite suppression
- How to manage nausea on semaglutide — the full nausea management protocol
- Access to your clinician for dose timing decisions between scheduled visits
What to do next
If you are starting GLP-1 therapy, read about how to talk to your doctor about starting GLP-1 therapy so you understand what to expect at the first visit and how the titration schedule will be explained.
FAQ
What is the GLP-1 titration schedule? Semaglutide titrates from 0.25mg to 2.4mg over 16-20 weeks. Tirzepatide titrates from 2.5mg to 15mg over 20-24 weeks. Each dose level lasts 4 weeks, but the schedule can be extended if side effects persist.
How long do GLP-1 side effects last? Side effects (nausea, constipation, fatigue) are most intense in the first 2 weeks of each dose increase and typically resolve by week 3-4. If they persist beyond week 3, your clinician may hold the dose longer before increasing.
Can I increase my GLP-1 dose faster than the standard schedule? Accelerating the schedule is not recommended. The standard timeline is designed to minimize side effects and maximize adherence. Faster titration increases the risk of discontinuation due to intolerable side effects.
What should I do if I cannot tolerate the next dose increase? Hold at the current dose for an additional 2-4 weeks
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/